TwinBeech Capital’s Ocular Therapeutix OCUL Stock Holding History

TwinBeech Capital’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-140,350	Closed	-$1.7M	–	754
2025 Q4	$1.7M	Buy	140,350 +77,504	+123%	+$941K	0.12%	218
2025 Q3	$735K	Buy	+62,846	New	+$752K	0.03%	352
2021 Q3	–	Sell	-13,311	Closed	-$189K	–	709
2021 Q2	$189K	Buy	+13,311	New	+$202K	0.02%	418

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TwinBeech Capital's OCUL Position: Q1 2026 in Review

TwinBeech Capital sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 140,350 shares — an estimated $1.7M sold.

TwinBeech Capital first reported a position in OCUL in Q2 2021 and held it in 3 quarters. The position peaked at $1.7M in Q4 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

TwinBeech Capital reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
TwinBeech Capital sold 140,350 Ocular Therapeutix shares in Q1 2026, an estimated $1.7M.
TwinBeech Capital first reported a position in Ocular Therapeutix in Q2 2021 and held it in 3 quarters.
TwinBeech Capital's Ocular Therapeutix position peaked at $1.7M in Q4 2025.
271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.